| Literature DB >> 28523108 |
Cheng Mo1,2, Zhang Zhang3, Christopher P Guise4,5, Xueqiang Li1,2, Jinfeng Luo1, Zhengchao Tu1, Yong Xu1, Adam V Patterson4,5, Jeff B Smaill4,5, Xiaomei Ren3, Xiaoyun Lu3, Ke Ding3.
Abstract
A series of 2-aminopyrimidine derivatives were designed and synthesized as highly selective FGFR4 inhibitors. One of the most promising compounds 2n tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymatic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3. The compound selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM. Furthermore, 2n exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, respectively.Entities:
Keywords: Selective FGFR4 inhibitor; breast cancer; hepatocellular carcinoma; targeted therapy
Year: 2017 PMID: 28523108 PMCID: PMC5430393 DOI: 10.1021/acsmedchemlett.7b00091
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345